128 related articles for article (PubMed ID: 10529789)
1. New perspectives on the molecular basis of hereditary bone tumours.
McCormick C; Duncan G; Tufaro F
Mol Med Today; 1999 Nov; 5(11):481-6. PubMed ID: 10529789
[TBL] [Abstract][Full Text] [Related]
2. The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.
Duncan G; McCormick C; Tufaro F
J Clin Invest; 2001 Aug; 108(4):511-6. PubMed ID: 11518722
[No Abstract] [Full Text] [Related]
3. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate.
McCormick C; Leduc Y; Martindale D; Mattison K; Esford LE; Dyer AP; Tufaro F
Nat Genet; 1998 Jun; 19(2):158-61. PubMed ID: 9620772
[TBL] [Abstract][Full Text] [Related]
4. EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis.
Stickens D; Brown D; Evans GA
Dev Dyn; 2000 Jul; 218(3):452-64. PubMed ID: 10878610
[TBL] [Abstract][Full Text] [Related]
5. Association of EXT1 and EXT2, hereditary multiple exostoses gene products, in Golgi apparatus.
Kobayashi S; Morimoto K; Shimizu T; Takahashi M; Kurosawa H; Shirasawa T
Biochem Biophys Res Commun; 2000 Feb; 268(3):860-7. PubMed ID: 10679296
[TBL] [Abstract][Full Text] [Related]
6. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses.
Pacifici M
Matrix Biol; 2018 Oct; 71-72():28-39. PubMed ID: 29277722
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype correlation in hereditary multiple exostoses.
Francannet C; Cohen-Tanugi A; Le Merrer M; Munnich A; Bonaventure J; Legeai-Mallet L
J Med Genet; 2001 Jul; 38(7):430-4. PubMed ID: 11432960
[TBL] [Abstract][Full Text] [Related]
8. Hereditary multiple exostoses and heparan sulfate polymerization.
Zak BM; Crawford BE; Esko JD
Biochim Biophys Acta; 2002 Dec; 1573(3):346-55. PubMed ID: 12417417
[TBL] [Abstract][Full Text] [Related]
9. Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes.
Bernard MA; Hall CE; Hogue DA; Cole WG; Scott A; Snuggs MB; Clines GA; Lüdecke HJ; Lovett M; Van Winkle WB; Hecht JT
Cell Motil Cytoskeleton; 2001 Feb; 48(2):149-62. PubMed ID: 11169766
[TBL] [Abstract][Full Text] [Related]
10. Transgenic expression of the EXT2 gene in developing chondrocytes enhances the synthesis of heparan sulfate and bone formation in mice.
Morimoto K; Shimizu T; Furukawa K; Morio H; Kurosawa H; Shirasawa T
Biochem Biophys Res Commun; 2002 Apr; 292(4):999-1009. PubMed ID: 11944914
[TBL] [Abstract][Full Text] [Related]
11. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.
McCormick C; Duncan G; Goutsos KT; Tufaro F
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):668-73. PubMed ID: 10639137
[TBL] [Abstract][Full Text] [Related]
12. Reevaluation of a genetic model for the development of exostosis in hereditary multiple exostosis.
Hall CR; Cole WG; Haynes R; Hecht JT
Am J Med Genet; 2002 Sep; 112(1):1-5. PubMed ID: 12239711
[TBL] [Abstract][Full Text] [Related]
13. [Multiple exostoses].
Toguchida J; Nagayama S
Nihon Rinsho; 2000 Jul; 58(7):1473-8. PubMed ID: 10921326
[TBL] [Abstract][Full Text] [Related]
14. Novel mutation in the EXT-1 gene in an Iranian family affected with hereditary multiple exostoses.
Foroughmand AM; Galehdari H; Rasouli M; Mohammadian G; Mohammadi M
Pak J Biol Sci; 2008 Apr; 11(7):1037-41. PubMed ID: 18810975
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes.
Wuyts W; Van Hul W
Hum Mutat; 2000; 15(3):220-7. PubMed ID: 10679937
[TBL] [Abstract][Full Text] [Related]
16. Novel EXT1 and EXT2 mutations in hereditary multiple exostoses families of Indian origin.
Vanita V; Sperling K; Sandhu HS; Sandhu PS; Singh JR
Genet Test Mol Biomarkers; 2009 Feb; 13(1):43-9. PubMed ID: 19309273
[TBL] [Abstract][Full Text] [Related]
17. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1).
Ahn J; Lüdecke HJ; Lindow S; Horton WA; Lee B; Wagner MJ; Horsthemke B; Wells DE
Nat Genet; 1995 Oct; 11(2):137-43. PubMed ID: 7550340
[TBL] [Abstract][Full Text] [Related]
18. The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis.
Senay C; Lind T; Muguruma K; Tone Y; Kitagawa H; Sugahara K; Lidholt K; Lindahl U; Kusche-Gullberg M
EMBO Rep; 2000 Sep; 1(3):282-6. PubMed ID: 11256613
[TBL] [Abstract][Full Text] [Related]
19. Heparan sulfate in skeletal development, growth, and pathology: the case of hereditary multiple exostoses.
Huegel J; Sgariglia F; Enomoto-Iwamoto M; Koyama E; Dormans JP; Pacifici M
Dev Dyn; 2013 Sep; 242(9):1021-32. PubMed ID: 23821404
[TBL] [Abstract][Full Text] [Related]
20. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate.
Lind T; Tufaro F; McCormick C; Lindahl U; Lidholt K
J Biol Chem; 1998 Oct; 273(41):26265-8. PubMed ID: 9756849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
